1. |
House TW. The precision medicine initiative 2015. Available at: https://obamawhitehouse.archives.gov/precision-medicine.
|
2. |
吴思竹, 钱庆, 杨林. 中国、美国、英国精准医学计划比较研究. 中国医院管理, 2017, 37(9): 77-80.
|
3. |
焦怡琳, 王吉春, 张群, 等. 中国在精准医学领域面临的机遇与挑战. 中国公共卫生管理, 2015, 31(5): 601-603.
|
4. |
Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? Pharmacogenomics J, 2017, 17(5): 395-402.
|
5. |
Daly AK. Pharmacogenetics: a general review on progress to date. Br Med Bull, 2017, 124(1): 65-79.
|
6. |
Gross T, Daniel J. Overview of pharmacogenomic testing in clinical practice. Ment Health Clin, 2018, 8(5): 235-241.
|
7. |
Caudle KE, Keeling NJ, Klein TE, et al. Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward. Pharmacogenomics, 2018, 19(10): 847-860.
|
8. |
健康界. 国家卫健委, 医保局共识: 将卫生技术评估用于医保准入. Available at: https://www.cn-healthcare.com/article/20181130/content-511652.html.
|
9. |
Pitini E, De Vito C, Marzuillo C, et al. How is genetic testing evaluated? A systematic review of the literature. Eur J Hum Genet, 2018, 26(5): 605-615.
|
10. |
Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. Oxford: Oxford University Press, 2004: 217-233.
|
11. |
Public Health Genomics. ACCE Model List of 44 Targeted Questions. Available at: https://www.cdc.gov/genomics/gtesting/acce/acce_proj.htm.
|
12. |
Medical Service Advisory Committee, Australian Government, Department of Health. Clinical Utility Card for heritable mutations which increase risk in disease area. Available at: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/9C7DCF1C2DD56CBECA25801000123C32/$File/Glossary-CUC-proforma.pdf.
|
13. |
Kroese M, Zimmern RL, Farndon P, et al. How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network. Eur J Hum Genet, 2007, 15(9): 917-921.
|
14. |
Schmidtke J, Cassiman JJ. The EuroGentest clinical utility gene cards. Eur J Hum Genet, 2010, 18(9): 1071.
|
15. |
Fleeman N, Martin Saborido C, Payne K, et al. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess, 2011, 15(33): 1-102.
|
16. |
Giacomini M, Miller F, Browman G. Confronting the "gray zones" of technology assessment: evaluating genetic testing services for public insurance coverage in Canada. Int J Technol Assess Health Care, 2003, 19(2): 301-316.
|
17. |
Gutiérrez-Ibarluzea I. Personalised health care, the need for reassessment. A HTA perspective far beyond cost-effectiveness. Ital J Public Health, 2012, 9(4): e8653.1-e8653.9.
|
18. |
Merlin T, Farah C, Schubert C, et al. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies. Med Decis Making, 2013, 33(3): 333-342.
|
19. |
Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford university press, 2015.
|
20. |
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med, 2009, 11(1): 3-14.
|
21. |
CDC. Evaluation of Genomic Applications in Practice and Prevention (EGAPP). Available at: https://www.cdc.gov/egappreviews/process.html.
|
22. |
NICE. Diagnostics Assessment Programme. Available at: http://www.sciencedirect.com/science/article/pii/S2211883712000068.
|
23. |
Morton S, Berg A, Levit L, et al. Finding what works in health care: standards for systematic reviews. New York: National Academies Press, 2011.
|
24. |
Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med, 2010, 12(11): 680-683.
|
25. |
Kuntz K, Sainfort F, Butler M, et al. Decision and simulation modeling in systematic reviews, 2013. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23534078.
|
26. |
刘跃华, 戴纯, 杜天天, 等. 美国肿瘤药物价值评价框架的启示. 中国医疗保险, 2019, (5): 69-71.
|
27. |
基因谷. 全国肿瘤体细胞突变高通量测序检测第一次室间质量评价满分单位. Available at: http://www.sohu.com/a/139038550_733985.
|